Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN®) and Follow-Up Considerations/Recommendations

Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN®) and Follow-Up Considerations/Recommendations

Alfredo Adán,1 Francisco Cabrera,2 Marta S Figueroa,3 Enrique Cervera,4 Francisco J Ascaso,5 Patricia Udaondo,6 Maximino Abraldes,7 Miguel Ángel Reyes,8 Marta Pazos,1 Bernardete Pessoa,9 Félix Armadá10 1Hospital Clínic de Barcelona, Barcelona, S...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Adán A, Cabrera F, Figueroa MS, Cervera E, Ascaso FJ, Udaondo P, Abraldes M, Reyes MÁ, Pazos M, Pessoa B, Armadá F
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2020
Materias:
diabetic macular edema
dme
fluocinolone acetonide implant therapy
iluvien
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/a3baca9339cb4dc98ad807051a1c4c81
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:a3baca9339cb4dc98ad807051a1c4c81
record_format dspace
spelling oai:doaj.org-article:a3baca9339cb4dc98ad807051a1c4c812021-12-02T11:05:07ZClinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN®) and Follow-Up Considerations/Recommendations1177-5483https://doaj.org/article/a3baca9339cb4dc98ad807051a1c4c812020-07-01T00:00:00Zhttps://www.dovepress.com/clinical-decision-criteria-to-identify-recurrent-diabetic-macular-edem-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Alfredo Adán,1 Francisco Cabrera,2 Marta S Figueroa,3 Enrique Cervera,4 Francisco J Ascaso,5 Patricia Udaondo,6 Maximino Abraldes,7 Miguel Ángel Reyes,8 Marta Pazos,1 Bernardete Pessoa,9 Félix Armadá10 1Hospital Clínic de Barcelona, Barcelona, Spain; 2Complejo Hospitalario Universitario Insular Materno-Lnfantil de Gran Canaria, Las Palmas de Gran Canaria, Spain; 3Hospital Universitario Ramón y Cajal, Madrid, Spain; 4Hospital General Universitario de Valencia, Valencia, Spain; 5Hospital Clínico Universitario Lozano Blesa de Zaragoza, Aragon Health Research Institute (IIS Aragon), Zaragoza, Spain; 6Hospital Universitario y Politécnico la Fe de Valencia, Valencia, Spain; 7Complexo Hospitalario Universitario de Santiago de Compostela, Universidad de Santiago de Compostela, Instituto Oftalmológico Gómez-Ulla, Santiago de Compostela, Spain; 8Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain; 9Centro Hospitalar e Universitário do Porto, Hospital Geral de Santo António, Porto, Portugal; 10Hospital Universitario La Paz, Madrid, SpainCorrespondence: Alfredo Adán Tel +34932275667Fax +34932275605Email amadan@clinic.catAbstract: Current management of diabetic macular edema (DME) predominantly involves treatment with short-acting intravitreal injections of anti-vascular endothelial growth factors (anti-VEGFs) and/or corticosteroids; however, short-acting therapies (lasting between 1 and 6 months) require frequent injections to maintain efficacy, meaning a considerable treatment burden for diabetic patients with multiple comorbidities. Continuous injections needed in some cases are an economic burden for patients/healthcare system, so real-life clinical practice tends to adopt a reactive approach, ie, watch and wait for worsening symptoms, which consequently increases the risk of undertreatment and edema recurrence. On March 7th 2019, a group of experts in retinal medicine and surgery held a roundtable meeting in Madrid, Spain to discuss how to (1) optimize clinical outcomes through earlier use of fluocinolone acetonide (FAc) implant (ILUVIEN®) in patients with persistent or recurrent DME despite therapy; and, (2) to provide guidance to assist physicians in deciding which patients should be treated with ILUVIEN. In this regard, a 36-month follow-up consensus protocol is presented. In conclusion, patients that achieve a complete or partial anatomical, and preferably functional, response following one or two intravitreal dexamethasone implants, but with recurrence of edema after 3– 4 months, are deemed by the authors most likely to benefit from ILUVIEN, and the switch to FAc implant should not be delayed more than 12 months after the initiation of at least the first dexamethasone implant.Keywords: diabetic macular edema, DME, fluocinolone acetonide implant therapy, ILUVIENAdán ACabrera FFigueroa MSCervera EAscaso FJUdaondo PAbraldes MReyes MÁPazos MPessoa BArmadá FDove Medical Pressarticlediabetic macular edemadmefluocinolone acetonide implant therapyiluvienOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 14, Pp 2091-2107 (2020)
institution DOAJ
collection DOAJ
language EN
topic diabetic macular edema
dme
fluocinolone acetonide implant therapy
iluvien
Ophthalmology
RE1-994
spellingShingle diabetic macular edema
dme
fluocinolone acetonide implant therapy
iluvien
Ophthalmology
RE1-994
Adán A
Cabrera F
Figueroa MS
Cervera E
Ascaso FJ
Udaondo P
Abraldes M
Reyes MÁ
Pazos M
Pessoa B
Armadá F
Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN®) and Follow-Up Considerations/Recommendations
description Alfredo Adán,1 Francisco Cabrera,2 Marta S Figueroa,3 Enrique Cervera,4 Francisco J Ascaso,5 Patricia Udaondo,6 Maximino Abraldes,7 Miguel Ángel Reyes,8 Marta Pazos,1 Bernardete Pessoa,9 Félix Armadá10 1Hospital Clínic de Barcelona, Barcelona, Spain; 2Complejo Hospitalario Universitario Insular Materno-Lnfantil de Gran Canaria, Las Palmas de Gran Canaria, Spain; 3Hospital Universitario Ramón y Cajal, Madrid, Spain; 4Hospital General Universitario de Valencia, Valencia, Spain; 5Hospital Clínico Universitario Lozano Blesa de Zaragoza, Aragon Health Research Institute (IIS Aragon), Zaragoza, Spain; 6Hospital Universitario y Politécnico la Fe de Valencia, Valencia, Spain; 7Complexo Hospitalario Universitario de Santiago de Compostela, Universidad de Santiago de Compostela, Instituto Oftalmológico Gómez-Ulla, Santiago de Compostela, Spain; 8Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain; 9Centro Hospitalar e Universitário do Porto, Hospital Geral de Santo António, Porto, Portugal; 10Hospital Universitario La Paz, Madrid, SpainCorrespondence: Alfredo Adán Tel +34932275667Fax +34932275605Email amadan@clinic.catAbstract: Current management of diabetic macular edema (DME) predominantly involves treatment with short-acting intravitreal injections of anti-vascular endothelial growth factors (anti-VEGFs) and/or corticosteroids; however, short-acting therapies (lasting between 1 and 6 months) require frequent injections to maintain efficacy, meaning a considerable treatment burden for diabetic patients with multiple comorbidities. Continuous injections needed in some cases are an economic burden for patients/healthcare system, so real-life clinical practice tends to adopt a reactive approach, ie, watch and wait for worsening symptoms, which consequently increases the risk of undertreatment and edema recurrence. On March 7th 2019, a group of experts in retinal medicine and surgery held a roundtable meeting in Madrid, Spain to discuss how to (1) optimize clinical outcomes through earlier use of fluocinolone acetonide (FAc) implant (ILUVIEN®) in patients with persistent or recurrent DME despite therapy; and, (2) to provide guidance to assist physicians in deciding which patients should be treated with ILUVIEN. In this regard, a 36-month follow-up consensus protocol is presented. In conclusion, patients that achieve a complete or partial anatomical, and preferably functional, response following one or two intravitreal dexamethasone implants, but with recurrence of edema after 3– 4 months, are deemed by the authors most likely to benefit from ILUVIEN, and the switch to FAc implant should not be delayed more than 12 months after the initiation of at least the first dexamethasone implant.Keywords: diabetic macular edema, DME, fluocinolone acetonide implant therapy, ILUVIEN
format article
author Adán A
Cabrera F
Figueroa MS
Cervera E
Ascaso FJ
Udaondo P
Abraldes M
Reyes MÁ
Pazos M
Pessoa B
Armadá F
author_facet Adán A
Cabrera F
Figueroa MS
Cervera E
Ascaso FJ
Udaondo P
Abraldes M
Reyes MÁ
Pazos M
Pessoa B
Armadá F
author_sort Adán A
title Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN®) and Follow-Up Considerations/Recommendations
title_short Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN®) and Follow-Up Considerations/Recommendations
title_full Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN®) and Follow-Up Considerations/Recommendations
title_fullStr Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN®) and Follow-Up Considerations/Recommendations
title_full_unstemmed Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN®) and Follow-Up Considerations/Recommendations
title_sort clinical-decision criteria to identify recurrent diabetic macular edema patients suitable for fluocinolone acetonide implant therapy (iluvien®) and follow-up considerations/recommendations
publisher Dove Medical Press
publishDate 2020
url https://doaj.org/article/a3baca9339cb4dc98ad807051a1c4c81
work_keys_str_mv AT adana clinicaldecisioncriteriatoidentifyrecurrentdiabeticmacularedemapatientssuitableforfluocinoloneacetonideimplanttherapyiluvienregandfollowupconsiderationsrecommendations
AT cabreraf clinicaldecisioncriteriatoidentifyrecurrentdiabeticmacularedemapatientssuitableforfluocinoloneacetonideimplanttherapyiluvienregandfollowupconsiderationsrecommendations
AT figueroams clinicaldecisioncriteriatoidentifyrecurrentdiabeticmacularedemapatientssuitableforfluocinoloneacetonideimplanttherapyiluvienregandfollowupconsiderationsrecommendations
AT cerverae clinicaldecisioncriteriatoidentifyrecurrentdiabeticmacularedemapatientssuitableforfluocinoloneacetonideimplanttherapyiluvienregandfollowupconsiderationsrecommendations
AT ascasofj clinicaldecisioncriteriatoidentifyrecurrentdiabeticmacularedemapatientssuitableforfluocinoloneacetonideimplanttherapyiluvienregandfollowupconsiderationsrecommendations
AT udaondop clinicaldecisioncriteriatoidentifyrecurrentdiabeticmacularedemapatientssuitableforfluocinoloneacetonideimplanttherapyiluvienregandfollowupconsiderationsrecommendations
AT abraldesm clinicaldecisioncriteriatoidentifyrecurrentdiabeticmacularedemapatientssuitableforfluocinoloneacetonideimplanttherapyiluvienregandfollowupconsiderationsrecommendations
AT reyesma clinicaldecisioncriteriatoidentifyrecurrentdiabeticmacularedemapatientssuitableforfluocinoloneacetonideimplanttherapyiluvienregandfollowupconsiderationsrecommendations
AT pazosm clinicaldecisioncriteriatoidentifyrecurrentdiabeticmacularedemapatientssuitableforfluocinoloneacetonideimplanttherapyiluvienregandfollowupconsiderationsrecommendations
AT pessoab clinicaldecisioncriteriatoidentifyrecurrentdiabeticmacularedemapatientssuitableforfluocinoloneacetonideimplanttherapyiluvienregandfollowupconsiderationsrecommendations
AT armadaf clinicaldecisioncriteriatoidentifyrecurrentdiabeticmacularedemapatientssuitableforfluocinoloneacetonideimplanttherapyiluvienregandfollowupconsiderationsrecommendations
_version_ 1718396305913413632

Ejemplares similares